Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of gemcitabine, cisplatin and durvalumab or pembrolizumab plus live butyrate-producing bacteria for unresectable biliary tract cancer
jRCTs031250774Phase 2Recruiting
- Start
- Mar 2026
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of durvalumab, pembrolizumab, gemcitabine, cisplatin and clostridium butyricum in intrahepatic cholangiocarcinoma (ICC), hilar cholangiocarcinoma (HC), cholangiocarcinoma (CCA) and 3 more (2 arms). Primary endpoint: 1-year overall survival rate. Started Mar 2026; status: recruiting.
02
Drugs
03
Conditions
intrahepatic cholangiocarcinoma (ICC)hilar cholangiocarcinoma (HC)cholangiocarcinoma (CCA)gallbladder cancerAmpullary cancer (AC)
Beyond the preview
Go deeper on jRCTs031250774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250774.